États-Unis · Plateformes & données · Finviz

Fractyl Health Meets Six-Month Primary Endpoint in Revita Obesity Trial, Supporting FDA Submission Plans

Publié par Finviz · États-Unis il y a 3 j

Fractyl Health reports statistically significant reductions in weight regain following GLP-1 discontinuation, advancing its Revita treatment toward a potential FDA submission in…

Lire l'article complet sur Finviz Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finviz.com)

Fractyl Health Meets Six-Month Primary Endpoint in Revita Obesity Trial, Supporting FDA Submission Plans

À lire aussi

30,000 Shares of Truist Financial Corporation $TFC Bought by Fortitude Financial LLC

Rocky Mountain Chocolate Factory outlines strategic alternatives after $6.6M Durango sale-leaseback and $2M loan

Pre-IPO Anduril Stock Climbs 50% in 5 Months

Blood clots are ‘incredibly common,’ even for pro athletes like Jalen Hurts. Here’s what to know.

Earnings call transcript: Zions Bancorporation tops Q3 2026 EPS forecast

Anthropic is AI trade's last big hope for a major IPO this year

Fractyl Health Meets Six-Month Primary Endpoint in Revita Obesity Trial, Supporting FDA Submission Plans

Partager

À lire aussi

30,000 Shares of Truist Financial Corporation $TFC Bought by Fortitude Financial LLC

Rocky Mountain Chocolate Factory outlines strategic alternatives after $6.6M Durango sale-leaseback and $2M loan

Pre-IPO Anduril Stock Climbs 50% in 5 Months

Blood clots are ‘incredibly common,’ even for pro athletes like Jalen Hurts. Here’s what to know.

Earnings call transcript: Zions Bancorporation tops Q3 2026 EPS forecast

Anthropic is AI trade's last big hope for a major IPO this year